MENU
+Compare
SLS
Stock ticker: NASDAQ
AS OF
Dec 20, 04:59 PM (EDT)
Price
$0.90
Change
-$0.00 (-0.00%)
Capitalization
63.39M

SLS SELLAS Life Sciences Group Forecast, Technical & Fundamental Analysis

a developer of biopharmaceuticals

Industry Biotechnology
SLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for SLS with price predictions
Dec 20, 2024

SLS sees MACD Histogram just turned negative

SLS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 22, 2024. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 42 instances where the indicator turned negative. In of the 42 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 22, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on SLS as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

SLS moved below its 50-day moving average on November 21, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for SLS crossed bearishly below the 50-day moving average on December 02, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

The 50-day moving average for SLS moved below the 200-day moving average on November 21, 2024. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for SLS entered a downward trend on December 20, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SLS's RSI Oscillator exited the oversold zone, of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 19 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SLS advanced for three days, in of 263 cases, the price rose further within the following month. The odds of a continued upward trend are .

SLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.932) is normal, around the industry mean (14.556). P/E Ratio (0.000) is within average values for comparable stocks, (87.563). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.739). SLS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (0.000) is also within normal values, averaging (256.215).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SLS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
SLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

SLS is expected to report earnings to -10 cents per share on March 20

SELLAS Life Sciences Group SLS Stock Earnings Reports
Q4'24
Est.
$-0.10
Q3'24
Beat
by $0.03
Q2'24
Beat
by $0.04
Q1'24
Beat
by $0.02
Q4'23
Missed
by $0.22
The last earnings report on November 13 showed earnings per share of -10 cents, beating the estimate of -12 cents. With 1.21M shares outstanding, the current market capitalization sits at 63.39M.
A.I. Advisor
published General Information

General Information

a developer of biopharmaceuticals

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
7 Times Square
Phone
+1 646 200-5278
Employees
16
Web
https://www.sellaslifesciences.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IMRX2.000.16
+8.70%
Immuneering Corp
AKBA1.830.04
+2.23%
Akebia Therapeutics
RYAN64.010.86
+1.36%
Ryan Specialty Holdings
MMC211.741.39
+0.66%
Marsh & McLennan Companies
RES5.63-0.02
-0.35%
RPC

SLS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, SLS has been loosely correlated with FULC. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SLS jumps, then FULC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLS
1D Price
Change %
SLS100%
-1.11%
FULC - SLS
48%
Loosely correlated
+7.94%
NKTR - SLS
42%
Loosely correlated
-1.35%
SNPX - SLS
34%
Loosely correlated
+19.69%
AXON - SLS
32%
Poorly correlated
+2.60%
MDGL - SLS
30%
Poorly correlated
+5.12%
More